Literature DB >> 7582247

Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression.

H Koizumi1, M Wakisaka, K Nakada, T Takakuwa, T Fujioka, N Yamate, T Uchikoshi.   

Abstract

The in vivo occurrence of apoptosis in neuroblastomas was investigated. Histologically, a number of tumour cells showed typical apoptotic changes, including cell shrinkage, condensed and fragmented nuclei, eosinophilic cytoplasm, and absence of the inflammatory response. These cells coincided closely with the so-called karyorrhectic cells. An electrophoretic DNA ladder, a functional hallmark of apoptosis, was demonstrated in four of six tumours, and DNA fragmentation was detected in situ by terminal deoxytransferase-mediated nick end-labelling in 26 of 35 tumour specimens (74%). The labelled cell counts ranged from 5 to 62 per 5000 tumour cells (mean +/- SD: 15.0 +/- 14.5). Immunoperoxidase staining revealed that an apoptosis-suppressing protein, bcl-2, was expressed abundantly in advanced-stage tumours, whereas it was absent from karyorrhectic-apoptotic cells. Several tumours with the potential for spontaneous regression were bcl-2-deficient. Immunostaining of the Fas receptor for apoptosis demonstrated that the tumour cells expressed this molecule on their cell surfaces. Our results provide evidence of apoptosis in neuroblastomas and suggest that bcl-2 and the Fas receptor may play a role in its regulatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582247     DOI: 10.1007/BF00196522

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  38 in total

Review 1.  Neuroblastoma. Pathology and biology.

Authors:  H Shimada
Journal:  Acta Pathol Jpn       Date:  1992-04

2.  The expression of "tissue" transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis).

Authors:  M Piacentini; L Fesus; M G Farrace; L Ghibelli; L Piredda; G Melino
Journal:  Eur J Cell Biol       Date:  1991-04       Impact factor: 4.492

Review 3.  Apoptosis and disease.

Authors:  D A Carson; J M Ribeiro
Journal:  Lancet       Date:  1993-05-15       Impact factor: 79.321

4.  Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death.

Authors:  J J Cohen; R C Duke
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

5.  Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance.

Authors:  J Searle; J F Kerr; C J Bishop
Journal:  Pathol Annu       Date:  1982

6.  Expression of bcl-2 gene product in neuroblastoma.

Authors:  P Ramani; Q L Lu
Journal:  J Pathol       Date:  1994-03       Impact factor: 7.996

7.  Stage II neuroblastoma. Adverse prognostic significance of lymph node involvement.

Authors:  J Ninane; J Pritchard; P H Morris Jones; J R Mann; J S Malpas
Journal:  Arch Dis Child       Date:  1982-06       Impact factor: 3.791

Review 8.  [Cardiac rhabdomyoma and apoptosis: are regression controlled by the body?].

Authors:  D Satge; B De Geeter
Journal:  Arch Mal Coeur Vaiss       Date:  1992-05

Review 9.  Apoptosis. Its significance in cancer and cancer therapy.

Authors:  J F Kerr; C M Winterford; B V Harmon
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

Review 10.  Apoptosis, oncosis, and necrosis. An overview of cell death.

Authors:  G Majno; I Joris
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

View more
  2 in total

1.  Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report.

Authors:  H B Hellquist; B Olejnicka; M Jadner; T Andersson; C Sederholm
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Lysosomal-associated protein multispanning transmembrane 5 gene (LAPTM5) is associated with spontaneous regression of neuroblastomas.

Authors:  Jun Inoue; Akiko Misawa; Yukichi Tanaka; Shizuko Ichinose; Yuriko Sugino; Hajime Hosoi; Tohru Sugimoto; Issei Imoto; Johji Inazawa
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.